 |
|
|
|
 |
|
|
| Article 1 to 10 out of 23 concerning Chemokine Therapeutics Corp.
|
-
Chemokine Therapeutics announces issuance of U.S. patent
(07/04/2008)
Chemokine Therapeutics Corp., a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that it has been granted U.S. Patent No. 7,378,098.Patent No. 7,378,098 entitled "CXC ...
-
Chemokine Therapeutics Announces Final Results of CTCE-9908 Phase I/II Clinical Trial in Late Stage Cancer Patients
(06/16/2008)
Chemokine Therapeutics Corp. announced positive data following the successful completion of the Phase I/II clinical trial for CTCE-9908, the Company's anti-cancer drug candidate. The primary objective of this Phase I/II clinical trial was to ...
-
Chemokine Therapeutics Announces New President And Chief Executive Officer
(04/18/2008)
Chemokine Therapeutics Corp. announced the appointment of Walter Korz as its new President and Chief Executive Officer (CEO). Mr. Korz succeeds Bashir Jaffer who held the position as Chief Executive Officer on an interim basis since December 2007. ...
-
Chemokine Therapeutics Receives Approval From Health Canada to Commence Phase II Study in Liver Cancer
(03/07/2008)
Chemokine Therapeutics Corp. announced that it has received a No Objection Letter from Health Canada allowing the Company to begin a Phase II study in liver cancer with its lead drug candidate, CTCE-9908. The Company also recently received FDA ...
-
Chemokine Therapeutics Receives Approval From FDA to Commence Phase II Study
(01/10/2008)
Chemokine Therapeutics Corp. announced that it has received notice from the U.S. Food and Drug Administration (FDA) allowing the Company to begin a Phase II study in liver cancer with its lead drug candidate, CTCE-9908.The Phase II trial will be a ...
-
Chemokine Therapeutics Announces New Directors
(12/19/2007)
Chemokine Therapeutics Corp. announced that Brian Kuhn, Bernard Byrd, George Kowalchuk and Reza Bahadori have joined the Board of Directors. They will fill vacancies created by the resignations of C. Richard Piazza, Michael Evans, John Osth and ...
-
Chemokine Therapeutics Continues Patient Therapy Using CTCE-9908 and Extends Closing of Its Phase I/II Clinical Trial
(12/12/2007)
Chemokine Therapeutics Corp. announced that the Company is continuing to treat patients with stable disease participating in the CTCE-9908 Phase I/II clinical trial. Although enrolment was completed at the end of September 2007, three patients with ...
-
Chemokine Therapeutics Withdraws Registration Statement and Implements a Cost Reduction Plan
(12/07/2007)
Chemokine Therapeutics Corp. announced that the Company has withdrawn the registration statement relating to the public offering, announced on May 30, 2007, due to market conditions. The Company is currently evaluating financing alternatives to fund ...
-
Chemokine Therapeutics Investigator Presents Encouraging Preliminary Results From CTCE-9908 Phase I/II Clinical Trial
(10/30/2007)
Chemokine Therapeutics Corp. announced preliminary results from the CTCE-9908 Phase I/II clinical trial by Dr. Sebastien Hotte, Lead Investigator. The preliminary results of the Phase I/II trial demonstrate that CTCE-9908 is well tolerated with no ...
-
Chemokine Therapeutics Announces Addition to Senior Management Team
(03/26/2007)
Chemokine Therapeutics Corp. announced the appointment of C. Richard Piazza as its new Chief Executive Officer (CEO). Mr. Piazza succeeds Dr. Hassan Salari who held the position since he founded the Company in 1998. Dr. Salari will continue to serve ...
|
|
|
|
|
Top